Clinical Edge Journal Scan

Obesity and advanced stage at diagnosis worsen recurrence rate in BC patients


 

Key clinical point: Obesity and advanced stage (stage III) at diagnosis of breast cancer (BC) were associated with a higher rate of recurrence and worse prognosis in patients with BC who achieved pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NCT).

Major finding: Obesity vs no obesity (P = .019) and stage III vs stage I-II BC at diagnosis (P = .0018) were significantly associated with worse invasive disease-free survival, with obesity demonstrating worse survival outcomes in stage III BC (hazard ratio 4.31; P = .006).

Study details: Findings are from a retrospective real-world analysis including 241 patients with stage I-III BC who had achieved pCR after receiving NCT.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Acevedo F et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. Sci Rep. 2022;12:21145 (Dec 7). Doi: 10.1038/s41598-022-25043-2

Recommended Reading

Long lasting benefit with dose-dense adjuvant chemotherapy in high-risk early BC
MDedge Hematology and Oncology
HR+/HER2− BC: Adjuvant abemaciclib+ET shows sustained positive benefit-risk profile
MDedge Hematology and Oncology
Breast cancer: Postmastectomy implant reconstruction increases risk for anaplastic large cell lymphoma
MDedge Hematology and Oncology
Axillary radiotherapy: A good treatment option for sentinel node-positive cT1-2 breast cancer
MDedge Hematology and Oncology
Axillary radiotherapy: A good treatment option for sentinel node-positive cT1-2 breast cancer
MDedge Hematology and Oncology
Acupuncture relieves AI-related joint pain for up to a year in BC patients
MDedge Hematology and Oncology
Triple-positive BC: Neoadjuvant pyrotinib+letrozole+dalpiciclib shows promise in phase 2
MDedge Hematology and Oncology
Selective internal radiation therapy effective and safe in patients with BC and hepatic metastasis
MDedge Hematology and Oncology
Prognostic impact of receptor conversion between primary breast cancer and bone metastases
MDedge Hematology and Oncology
Prognostic impact of receptor conversion between primary breast cancer and bone metastases
MDedge Hematology and Oncology